Components Page | Excipients Table | Allergens Table
| Manufacturer | Moderna | Pfizer-BioNTech | Janssen |
| Type | mRNA | mRNA | Adenovirus type 26 (Ad26)-vectored |
| Indicated Ages | 18 years and older | 12 years and older | 18 years and older |
| Dose | 0.5 mL | 0.3 mL | 0.5 mL |
| Schedule | 2 doses; 1 month apart | 2 doses; 3 weeks apart | 1 dose |
| Route | Intramuscular | Intramuscular | Intramuscular |
| Appearance | White to off-white suspension may contain white or translucent product-related particulates | White to off-white suspension and may contain white to off-white opaque amorphous particles. | Colorless to slightly yellow, clear to very opalescent. |
| Concentration | 100 mcg of nucleosidemodified messenger RNA (mRNA) encoding the pre-fusion stabilized Spike glycoprotein (S) of SARS-CoV-2 virus | 30 mcg of a nucleoside-modified messenger RNA (modRNA) encoding the viral spike (S) glycoprotein of SARS-CoV-2 | 5×1010 viral particles |
| Preservative | None | None | None |
| Adjuvant | None | None | None |
| Excipients | Lipids: -(SM-102, polyethylene glycol [PEG] 2000 dimyristoyl glycerol [DMG], 1.93 mg -Cholesterol -1,2-distearoyl-sn-glycero-3-phosphocholine [DSPC]) Tromethamine, 0.31 mg Tromethamine hydrochloride, 1.18 mg Acetic acid, 0.043 mg Sodium acetate, 0.12 mg Sucrose, 43.5 mg | Lipids: -(4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate), 0.43 mg -2[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide, 0.05 mg -1,2-distearoyl-sn-glycero-3-phosphocholine, 0.09 mg -Cholesterol, 0.2 mg Potassium chloride, 0.01 mg Phosphate Buffer: -Dibasic sodium phosphate dihydrate, 0.07 mg -Sodium chloride, 0.36 mg -Monobasic potassium phosphate, 0.01 mg Sucrose, 6 mg | Citric acid monohydrate Trisodium citrate dihydrate Ethanol 2-hydroxypropyl-β-cyclodextrin (HBCD) Polysorbate 80 Sodium chloride Sodium hydroxide Hydrochloric acid Amino Acids (from media) |
| Allergens | (SM-102, polyethylene glycol [PEG] 2000 dimyristoyl glycerol [DMG], 1.93 mg | 2[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide, 0.05 mg | Polysorbate 80 |
| Media | None | None | PER.C6® TetR Cell Line (no animal components) |
| Diluent | None | (0.9% Sodium Chloride Injection, USP) contributes an additional 2.16 mg sodium chloride per dose | None |
| Packaging | Multiple-dose Vials are supplied as a carton of 10 multiple-dose vials | Multipl-dose Vials (after dilution each vial contains 5 doses of 0.3 mL) | Multiple-dose Vials containing 5 doses (5 mL each) |
| Storage | • Stored frozen between -25°C to -15°C (-13°F to 5°F). • Do not store on dry ice or below -40ºC (-40ºF). • Vials can be stored refrigerated between 2° to 8°C (36° to 46°F) for up to 30 days prior to first use. • Unpunctured vials may be stored between 8° to 25°C (46° to 77°F) for up to 12 hours. • Do not refreeze once thawed. | • Prior to dilution, store at -80°C to -60°C (-112°F to -76°F). • After dilution, store the vaccine at 2°C to 25°C (35°F to 77°F). • Discard after 6 hours. | • The vials should be protected from light. • Unpunctured vials may be stored between 9°C to 25°C (47°F to 77°F) for up to 12 hours. • After the first dose has been withdrawn, the vial should be held between 2° to 8°C (36° to 46°F) for up to 6 hours or at room temperature (maximally 25°C/77°F) for up to 2 hours. • The vial should be discarded if the vaccine is not used within these times. |
| PI date | 12/2020 | 5/2021 | 3/2021 |
